ライフサイエンスコーパス: peptidomimetics

1 mRNAs into specific peptide analog polymers (peptidomimetics).

2 r-Psi[(Z and E)CH=C]-Pro-Arg-NH(2), 1 and 2, peptidomimetics.

3 nd to increase the water solubilities of the peptidomimetics.

4 rious ligands including TRP/NTL peptides and peptidomimetics.

5 opamine receptor modulating activity of such peptidomimetics.

6 s as components in pharmaceutical agents and peptidomimetics.

7 for incorporation into biologically relevant peptidomimetics.

8 erate the clinical utility of small molecule peptidomimetics.

9 or related amino acid motifs, and RGD-based peptidomimetics.

10 f strain-specific antibacterial peptides and peptidomimetics.

11 rent drug discovery efforts based on proline peptidomimetics.

12 and represent a novel approach to designing peptidomimetics.

13 luding linear peptides, cyclic peptides, and peptidomimetics.

14 opamine receptor modulating activity of such peptidomimetics.

15 andostatin-based conformationally restricted peptidomimetics.

16 ith delivery and formulation of peptides and peptidomimetics.

17 lts facilitate the design of new sandostatin peptidomimetics.

18 ning and refining therapeutically-attractive peptidomimetics.

19 al properties of this peptide by introducing peptidomimetics.

20 development of new small antiviral drugs or peptidomimetics.

21 tives are valuable pharmacological agents as peptidomimetics.

22 e introduced as the backbone modification in peptidomimetics.

23 ioisostere to provide protease resistance in peptidomimetics.

24 nthesis of biologically active molecules and peptidomimetics.

25 advantage of peptoids over other families of peptidomimetics.

26 ess to obtain the linear C-hydroxyalkylamido peptidomimetics.

27 synthesized and assayed libraries of mutant peptidomimetics.

28 ng conformationally constrained beta-hairpin peptidomimetics.

29 beta-Turn peptidomimetics 1 were designed to mimic hot spots of ne

30 in-protein interactions led us to design the peptidomimetics 1-3.

31 ects observed previously for PLG and the PLG peptidomimetics 2 and 4.

32 Peptidomimetics 3 and 4 also increased the percentage of

33 Peptidomimetics 3 and 4 were evaluated in vivo as modula

34 Peptidomimetics 3-5 each affected rotational behavior in

35 , butyl, and benzyl moieties to give the PLG peptidomimetics 3-5, respectively.

36 e isobutyl, butyl, and benzyl groups to give peptidomimetics 3-5, respectively.

37 ent study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizi

38 deprotection provided the epoxide-containing peptidomimetics, 4 and 5.

39 etter than in the corresponding syntheses of peptidomimetics A.

40 y of conformationally restrained dipeptides, peptidomimetics, alkaloids, and other biologically activ

41 gamma-secretase, SPP is inhibited by helical peptidomimetics and apparently contains a substrate-bind

42 hput synthesis of linear C-hydroxyalkylamido peptidomimetics and beta-turn cyclic peptidomimetics via

43 es a concrete basis for the design of potent peptidomimetics and nonpeptidic compounds to inhibit MLL

44 The peptidomimetics and pyrimidoindolones bind to both activ

45 -HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to thi

46 derived from the C-terminal tail of FGF23 or peptidomimetics and small-molecule organomimetics of the

47 nd their corresponding prolines in peptides, peptidomimetics, and natural products has motivated rese

48 Non-natural antimicrobial peptidomimetics are an ideal example of this, as they ha

49 Peptidomimetics are classes of molecules that mimic stru

50 s derived from amino acids, peptides, and/or peptidomimetics are described.

51 Thiazolino fused 2-pyridone peptidomimetics are of significant biological importance

52 Peptidomimetics are one set of probes used in the transi

53 ially addressable microchips of peptides and peptidomimetics are powerful tools for high-throughput b

54 Peptidomimetics are small protein-like molecules designe

55 e infusion of PF4 or PF4-related peptides or peptidomimetics as a way of beneficially stimulating "en

56 ion toward the design of cyclic peptides and peptidomimetics as calpain inhibitors.

57 ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specifi

58 ionally restricted beta-sheet breaker hybrid peptidomimetics (BSBHps).

59 olefin containing N-peptidyl-O-hydroxylamine peptidomimetics, by virtue of their inhibitory potency a

60 meostasis, and we suggest that ANXA1 and its peptidomimetics can be novel therapeutic targets in neur

61 Since phage-borne peptidomimetics can be selected from phage display libra

62 Peptides or peptidomimetics can mimic binding of the tethered ligand

63 with molecular libraries, demonstrating that peptidomimetics can provide valuable clues about recepto

64 leads to (i) a chemical library of putative peptidomimetics combining diverse azaheterocycles with t

65 5.5.6. and 5.6.5. spiro bicyclic lactam PLG peptidomimetics, compounds 3 and 4, respectively, was un

66 We have studied the efficacy of BH3 peptidomimetics consisting of the minimal death, or BH3,

67 latelets are less responsive to peptides and peptidomimetics containing an arginine-glycine-aspartic

68 Protein-tyrosine peptidomimetics containing nonhydrolyzable phosphotyrosi

69 ion events by receptor cleavage or synthetic peptidomimetics corresponding to the newly generated N-t

70 Exocyclic small peptidomimetics corresponding to three critical binding

71 The peptidomimetics described herein comprise a dibenzofuran

72 lustrate the procedure, a series of bivalent peptidomimetics directed toward the Trk receptors were p

73 Intermolecular stacking of the collapsed peptidomimetics, enabled by intermolecular hydrogen bond

74 h was followed by amino acids, peptides, and peptidomimetics for medicinal chemistry.

75 This approach may yield reagents such as peptidomimetics for novel diagnostic and therapeutic int

76 ecognition that could be useful in designing peptidomimetics for RNA targeting.

77 aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytoto

78 e present the synthesis of highly active RGD peptidomimetics for the alphavbeta3 integrin with remark

79 ve recently emerged as important examples of peptidomimetics for their interesting complexing propert

80 Peptidomimetics, FTI-276 and GGTI-287, inhibit the trans

81 ethod can be used to prepare imidazole based peptidomimetics, herein exemplified by the synthesis of

82 clodehydration to afford thiazole containing peptidomimetics in a short synthetic sequence.

83 ation of co-crystal structures of two potent peptidomimetics in complex with WDR5 establishes their s

84 g in a single process generating the desired peptidomimetics in good to excellent yields within a 25

85 of K-Ras as well as H- and N-Ras to the CAAX peptidomimetics in human tumor cell lines is not known.

86 beta-Strand peptidomimetics incorporating amino acid analogues based

87 This demonstrates that peptidomimetics, incorporating in this case the promiscu

88 elective novel class of non-thiol-containing peptidomimetics inhibits human tumor growth in whole ani

89 ate that the bioactive conformation of these peptidomimetics is close to the minimal energy conformat

90 polyhydroxylated piperidine and pyrrolidine peptidomimetics is described.

91 amino acid as the central core and acting as peptidomimetics, is presented.

92 with three different classes of inhibitors: peptidomimetics, isatins, and pyrimidoindolones.

93 Candidate inhibitors were isolated from a peptidomimetics library.

94 inoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacological pro

95 ogen receptor-coregulator interactions using peptidomimetics may be a viable therapeutic approach for

96 type of proteolytically stable FPR2-specific peptidomimetics may serve as valuable tools for future a

97 array comprising different types of cationic peptidomimetics obtained by a general monomer-based soli

98 ructure mimetic that can be used to generate peptidomimetics of biological interest.

99 ay a role in the potency of the gamma-lactam peptidomimetics of PLG, it does not appear to be the pri

100 6-Substituted bicyclic thiazolidine lactam peptidomimetics of Pro-Leu-Gly-NH(2) (1) were synthesize

101 r continuing program exploring glucose-based peptidomimetics of somatostatin (SRIF-14), we sought to

102 Two epoxide-containing peptidomimetics of the isopeptide, glutamyl-gamma-glutam

103 lecule for the preparation of collections of peptidomimetics or biologically active compounds based o

104 structural diverse inhibitors of Vif such as peptidomimetics or small organic molecules.

105 ttractive intermediates for the synthesis of peptidomimetics, polyheterocycles, and other multifuncti

106 Most of the peptidomimetics possessed high to moderate activity towa

107 s an important strategy for the synthesis of peptidomimetics (pseudo-peptides).

108 tems in Lepidoptera and aid in the design of peptidomimetics, pseudopeptides or small molecules capab

109 Peptidomimetics represent an important field in chemistr

110 pha/beta, alpha/gamma and alpha/delta hybrid peptidomimetics, respectively.

111 These non-thiol-containing peptidomimetics show exceptional selectivity for PGGTase

112 t the poor mimicry of the amide bond by many peptidomimetics stems from their inability to partake in

113 of drugs as they accept a large spectrum of peptidomimetics such as beta-lactam antibiotics, antivir

114 (Hydroxyethyl)urea peptidomimetics systematically altered at positions P2-P

115 ptides is a means to begin accessing complex peptidomimetics systematically.

116 search for effective cationic antimicrobial peptidomimetics targeting specific bacteria.

117 Herein, we review recent developments in peptidomimetics that are formed via heteroatom replaceme

118 -AApeptides are a new class of antibacterial peptidomimetics that are not prone to antibiotic resista

119 describe Neoseptins, chemically synthesized peptidomimetics that bear no structural similarity to th

120 to focus our attention on short peptides or peptidomimetics that behave as LMWGs.

121 a-D-glucose have been employed to synthesize peptidomimetics that bind the SRIF receptors on AtT-20 m

122 gn, synthesis, and evaluation of macrocyclic peptidomimetics that bind to WD repeat domain 5 (WDR5) a

123 menable to the development of small molecule peptidomimetics that could be used to modulate NER repai

124 ar weight drugs against NS3-4A are substrate peptidomimetics that have a similar binding and resistan

125 n order to obtain gold(III)-based anticancer peptidomimetics that might specifically target two pepti

126 A series of beta-diketone derivatives of RGD peptidomimetics that selectively bind to alphavbeta3 and

127 he development of D-enantiomer antimicrobial peptidomimetics that target bacterial membranes of certa

128 bination of beta-diketone derivatives of RGD peptidomimetics that target cell surface integrins alpha

129 be taken into account in designing potential peptidomimetics that target P. gingivalis adherence and

130 date prodrugs (8-10) of phosphate-containing peptidomimetics that target the SH2 domain were synthesi

131 Similar to peptides and other peptidomimetics, these well-defined synthetic macromolec

132 ssess several features that are desirable in peptidomimetics; they are easily synthesized, fold into

133 our previously developed strategy of dimeric peptidomimetics to address the hypothesis that loop 4 sm

134 otective antibodies may facilitate design of peptidomimetics to focus vaccine responses on protective

135 The ability of these peptidomimetics to increase the binding of agonist N-pro

136 We report herein the capacity of sugar-based peptidomimetics to inhibit both Abeta1-42 early oligomer

137 rturbations would have on the ability of the peptidomimetics to modulate dopamine receptors.

138 present study, we designed a large number of peptidomimetics to target the MLL1/WDR5 interaction base

139 ylamido peptidomimetics and beta-turn cyclic peptidomimetics via "volatilizable" aminoalkyl functiona

140 ransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their

141 structural variation of these antibacterial peptidomimetics was investigated as a tool for optimizin

142 ical interaction site for rational design of peptidomimetics was localized to the loop1/domain3 of th

143 Furthermore, both peptidomimetics were able to attenuate the Gpp(NH)p-indu

144 Taurine-containing water-soluble peptidomimetics were designed and synthesized.

145 These peptidomimetics were designed to examine the following:

146 These peptidomimetics were evaluated in vivo as modulators of

147 Beta-turn cyclic peptidomimetics were generated by intramolecular S(N)Ar

148 Both the linear and the cyclic peptidomimetics were obtained with good to excellent yie

149 A series of vinyl sulfone-containing peptidomimetics were rationally designed, synthesized, a

150 These peptidomimetics were tested for their ability to enhance

151 The peptidomimetics were used at very low concentrations (10

152 Peptidomimetics where the 5-position of the imidazole ri

153 of the inhibitors that are on the market are peptidomimetics, where a conserved water molecule mediat

154 of this Pauli repulsion by employing common peptidomimetics, wherein the n --> pi* interaction is at

155 completely new, previously unknown family of peptidomimetics, which are hydrolytically stable and dis

156 Our study led to the design of high-affinity peptidomimetics, which bind to WDR5 with K(i) < 1 nM and

157 ysis of a novel class of heteroatom-modified peptidomimetics, which we shall call "oxyazapeptides".

158 affold was used for the preparation of model peptidomimetics, whose beta turn conformation was confir

159 hermore, optimization of the length of these peptidomimetics with an alternating cationic-hydrophobic

160 rovided two pairs of Pro-Leu-Gly-NH(2) (PLG) peptidomimetics with contrasting dopamine receptor modul

161 ro-Met-Leu resulted in the design of smaller peptidomimetics with enhanced affinity including Ac-pTyr

162 f Mfa1 and SspB and suggest that peptides or peptidomimetics with greater specific inhibitory activit

163 Peptoids constitute a class of peptidomimetics with potential as protease resistant, bi

164 Low molecular weight peptidomimetics with simple amphiphilic sequences can he

165 c compounds 1b and 3b provided the first PLG peptidomimetics with the ability to decrease the binding

166 on, and conformational analysis of the first peptidomimetics with two pendant, chiral nitronyl nitrox